Predictive Oncology Inc.(POAI)Earnings, Financials & Key Ratios
POAI•NASDAQ
$4.91
$27M mkt cap·Price updated May 5, 2026
AboutPredictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.Show more
- Revenue$2M-0.2%
- EBITDA-$10M+13.7%
- Net Income-$12M+12.7%
- EPS (Diluted)-2.24+35.6%
- Gross Margin49.12%-21.5%
- EBITDA Margin-630.85%+13.5%
- Operating Margin-673.69%+9.5%
- Net Margin-751.39%+12.5%
- ROE-302.42%-224.8%
- ROIC-473.83%+44.1%
POAI Key Insights
Predictive Oncology Inc. (POAI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 86 (top 14%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 35.8% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
POAI Price & Volume
Predictive Oncology Inc. (POAI) stock price & volume — 10-year historical chart
Loading chart...
POAI Growth Metrics
Predictive Oncology Inc. (POAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.49%
5 Years2.84%
3 Years4.56%
TTM-47.2%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-503.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-3436.58%
Return on Capital
10 Years-247.91%
5 Years-153.72%
3 Years-114.39%
Last Year-184.71%
POAI Peer Comparison
Predictive Oncology Inc. (POAI) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RXRX | 1.46B | 3.27 | -2.27 | 26.92% | -8.44% | -54.32% | 0.07 | |
 ABSI | 893.82M | 5.75 | -6.85 | -38.24% | -73.06% | -63.58% | 0.03 | |
 SDGR | 992.29M | 13.28 | -9.42 | 23.29% | -40.6% | -30.85% | 0.30 | |
 ACLX | 6.73B | 115.07 | -28.27 | -79.35% | -10.27% | -55.42% | 0.24 | |
 CDNA | 1.11B | 21.44 | -53.60 | 13.79% | -1.98% | -2.61% | 0.06 | |
 NTRA | 31.16B | 219.82 | -144.62 | 35.9% | -9.03% | -15.28% | 0.13 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 VCYT | 3.25B | 40.76 | 49.71 | 16.01% | 16.25% | 6.86% | 0.03 |
Compare POAI vs Peers
Predictive Oncology Inc. (POAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
POAI Income Statement
Predictive Oncology Inc. (POAI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 456.5K | 654.84K | 1.41M | 1.41M | 1.25M | 1.42M | 1.51M | 1.63M | 1.62M | 728.2K |
| Revenue Growth % | -30.24% | 43.45% | 115.57% | -0.01% | -11.28% | 13.45% | 5.97% | 8.12% | -0.24% | -47.2% |
| Cost of Goods Sold | 181.62K | 148.04K | 415.76K | 531.81K | 447.19K | 487.02K | 505.11K | 609.21K | 826.14K | 362.32K |
| COGS % of Revenue | 39.79% | 22.61% | 29.45% | 37.68% | 35.71% | 34.28% | 33.55% | 37.43% | 50.88% | - |
| Gross Profit | 274.88K▲ 0% | 506.79K▲ 84.4% | 995.89K▲ 96.5% | 879.75K▼ 11.7% | 805.08K▼ 8.5% | 933.66K▲ 16.0% | 1M▲ 7.1% | 1.02M▲ 1.8% | 797.68K▼ 21.7% | 365.87K▲ 0% |
| Gross Margin % | 60.21% | 77.39% | 70.55% | 62.32% | 64.29% | 65.72% | 66.45% | 62.57% | 49.12% | 50.24% |
| Gross Profit Growth % | -21.55% | 84.37% | 96.51% | -11.66% | -8.49% | 15.97% | 7.14% | 1.81% | -21.68% | - |
| Operating Expenses | 6.8M | 8.25M | 8.86M | 23.52M | 26.17M | 21.36M | 27.03M | 13.14M | 11.74M | 10.72M |
| OpEx % of Revenue | 1489.81% | 1260.37% | 627.44% | 1666.55% | 2089.41% | 1503.67% | 1795.73% | 807.04% | 722.81% | - |
| Selling, General & Admin | 5.64M | 8.25M | 7M | 11.69M | 10.94M | 11.71M | 12.47M | 9.06M | 8.89M | 8.51M |
| SG&A % of Revenue | 1236.11% | 1260.37% | 495.6% | 828.45% | 873.37% | 824.02% | 828.29% | 556.43% | 547.24% | - |
| Research & Development | 406K | 289K | 1.86M | 2.96M | 372.71K | 315.85K | 320.32K | 122.31K | 25.99K | 1.05M |
| R&D % of Revenue | 88.94% | 44.13% | 131.84% | 209.71% | 29.76% | 22.23% | 21.28% | 7.51% | 1.6% | - |
| Other Operating Expenses | 1.16M | 0 | 68.48K | 8.87M | 14.86M | 9.34M | 14.24M | 3.96M | 2.83M | 1.16M |
| Operating Income | -6.53M▲ 0% | -7.75M▼ 18.7% | -7.86M▼ 1.5% | -22.64M▼ 188.1% | -25.36M▼ 12.0% | -20.43M▲ 19.4% | -26.03M▼ 27.4% | -12.12M▲ 53.5% | -10.94M▲ 9.7% | -10.35M▲ 0% |
| Operating Margin % | -1429.59% | -1182.98% | -556.89% | -1604.23% | -2025.12% | -1437.95% | -1729.28% | -744.47% | -673.69% | -1421.38% |
| Operating Income Growth % | -48.33% | -18.7% | -1.48% | -188.05% | -11.99% | 19.45% | -27.44% | 53.45% | 9.72% | - |
| EBITDA | -6.44M | -7.68M | -7.71M | -21.94M | -24.34M | -19.09M | -24.72M | -11.87M | -10.24M | -9.41M |
| EBITDA Margin % | -1411.55% | -1172.05% | -546.43% | -1554.29% | -1943.28% | -1343.61% | -1642.06% | -729.43% | -630.85% | -1291.94% |
| EBITDA Growth % | -49.12% | -19.11% | -0.5% | -184.43% | -10.92% | 21.56% | -29.51% | 51.97% | 13.72% | 26.04% |
| D&A (Non-Cash Add-back) | 82.36K | 71.56K | 147.63K | 704.88K | 1.02M | 1.34M | 1.31M | 244.79K | 695.66K | 942.58K |
| EBIT | -6.53M | -6.05M | -7.86M | -13.77M | -12.48M | -13.47M | -15.27M | -12.12M | -10.94M | -84.04M |
| Net Interest Income | -3 | 0 | 0 | 0 | 0 | 0 | -10.65M | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3 | 0 | 0 | 0 | 0 | 0 | 10.65M | 0 | 0 | 0 |
| Other Income/Expense | -3 | 50.51K | -2.23M | 3.25M | -524.36K | 109.8K | 296.02K | 100.17K | 79.27K | -73.66M |
| Pretax Income | -6.53M▲ 0% | -7.75M▼ 18.7% | -10.09M▼ 30.2% | -19.39M▼ 92.2% | -25.88M▼ 33.5% | -20.32M▲ 21.5% | -25.74M▼ 26.7% | -12.02M▲ 53.3% | -10.86M▲ 9.6% | -84.01M▲ 0% |
| Pretax Margin % | -1429.59% | -1182.98% | -714.51% | -1373.71% | -2066.99% | -1430.22% | -1709.62% | -738.32% | -668.81% | -11537.01% |
| Income Tax | 0 | 50.5K | 0 | 0 | 0 | -661.66K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -0.65% | 0% | 0% | 0% | 3.26% | 0% | 0% | 0% | 0% |
| Net Income | -6.53M▲ 0% | -7.75M▼ 18.7% | -10.09M▼ 30.2% | -19.39M▼ 92.2% | -25.88M▼ 33.5% | -19.66M▲ 24.1% | -25.74M▼ 30.9% | -13.98M▲ 45.7% | -12.2M▲ 12.7% | -84.33M▲ 0% |
| Net Margin % | -1429.59% | -1182.98% | -714.51% | -1373.71% | -2066.99% | -1383.65% | -1709.62% | -859.13% | -751.39% | -11581.34% |
| Net Income Growth % | -36.23% | -18.7% | -30.21% | -92.25% | -33.49% | 24.06% | -30.93% | 45.67% | 12.75% | -503.68% |
| Net Income (Continuing) | -6.53M | -6M | -10.09M | -19.39M | -25.88M | -19.66M | -25.74M | -12.02M | -10.86M | -84.01M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.97M | -1.8M | -322.86K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -462.28▲ 0% | -188.69▲ 59.2% | -157.40▲ 16.6% | -137.20▲ 12.8% | -44.25▲ 67.7% | -7.20▲ 83.7% | -6.98▲ 3.1% | -3.48▲ 50.1% | -2.24▲ 35.6% | -116.48▲ 0% |
| EPS Growth % | -50.68% | 59.18% | 16.58% | 12.83% | 67.75% | 83.73% | 3.06% | 50.14% | 35.63% | -3436.58% |
| EPS (Basic) | -462.28 | -188.69 | -157.40 | -137.14 | -44.25 | -7.16 | -6.98 | -3.48 | -2.24 | - |
| Diluted Shares Outstanding | 14.12K | 31.82K | 64.08K | 143.5K | 597.51K | 2.74M | 3.69M | 4.01M | 5.45M | 724K |
| Basic Shares Outstanding | 14.12K | 31.82K | 64.08K | 141.33K | 584.99K | 2.73M | 3.69M | 4.01M | 5.45M | 724K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
POAI Balance Sheet
Predictive Oncology Inc. (POAI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.61M | 2.37M | 1.45M | 798.26K | 1.51M | 29.46M | 23.36M | 10.08M | 2.23M | 1.1M |
| Cash & Short-Term Investments | 2.05M | 766.19K | 162.15K | 150.83K | 678.33K | 28.2M | 22.07M | 8.73M | 734.67K | 181.67K |
| Cash Only | 1.76M | 766.19K | 162.15K | 150.83K | 678.33K | 28.2M | 22.07M | 8.73M | 734.67K | 181.67K |
| Short-Term Investments | 284.33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 38.92K | 805.01K | 729.88K | 297.06K | 256.88K | 354.2K | 331.2K | 277.64K | 745.57K | 26.01K |
| Days Sales Outstanding | 31.12 | 448.71 | 188.72 | 76.81 | 74.87 | 91 | 80.3 | 62.26 | 167.59 | 107.06 |
| Inventory | 272.21K | 265.05K | 241.07K | 190.16K | 289.54K | 387.68K | 430.49K | 480.8K | 385.73K | 37.99K |
| Days Inventory Outstanding | 547.05 | 653.46 | 211.63 | 130.51 | 236.32 | 290.55 | 311.08 | 288.07 | 170.42 | 128.99 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 526.8K | 69.63K | 359.95K | 858.29K |
| Total Non-Current Assets | 199.36K | 1.25M | 2.26M | 21.58M | 11.55M | 14.31M | 2.37M | 4.34M | 2.75M | 2.03M |
| Property, Plant & Equipment | 101.5K | 87.72K | 180.45K | 2.24M | 5.22M | 3.33M | 2.05M | 3.96M | 2.43M | 1.89M |
| Fixed Asset Turnover | 4.50x | 7.47x | 7.82x | 0.63x | 0.24x | 0.43x | 0.74x | 0.41x | 0.67x | 0.34x |
| Goodwill | 0 | 0 | 0 | 15.69M | 2.81M | 6.86M | 0 | 0 | 0 | 0 |
| Intangible Assets | 97.87K | 95.36K | 964.5K | 3.65M | 3.4M | 3.96M | 253.87K | 252.46K | 210.11K | 47.52K |
| Long-Term Investments | 0 | 1.07M | 1.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 1.07M | 1.11M | 0 | 116.26K | 167.06K | 75.62K | 124.1K | 102.51K | 406K |
| Total Assets | 2.81M▲ 0% | 3.62M▲ 29.1% | 3.71M▲ 2.3% | 22.38M▲ 503.3% | 13.06M▼ 41.6% | 43.77M▲ 235.1% | 25.73M▼ 41.2% | 14.42M▼ 44.0% | 4.97M▼ 65.5% | 3.14M▲ 0% |
| Asset Turnover | 0.16x | 0.18x | 0.38x | 0.06x | 0.10x | 0.03x | 0.06x | 0.11x | 0.33x | 0.17x |
| Asset Growth % | -50.15% | 29.09% | 2.34% | 503.28% | -41.63% | 235.14% | -41.21% | -43.98% | -65.51% | -235.87% |
| Total Current Liabilities | 1.57M | 932.34K | 3.66M | 10.87M | 9.34M | 3.24M | 3.88M | 3.95M | 3.59M | 79.49M |
| Accounts Payable | 220.11K | 140.46K | 445.69K | 3.16M | 1.37M | 1.02M | 943.45K | 1.33M | 1.14M | 2.72M |
| Days Payables Outstanding | 442.36 | 346.3 | 391.27 | 2.17K | 1.12K | 765.77 | 681.76 | 799.28 | 504.96 | 1.62K |
| Short-Term Debt | 0 | 0 | 1.63M | 5.26M | 4.43M | 0 | 0 | 150.41K | 0 | 627.91K |
| Deferred Revenue (Current) | 8K | 6.66K | 23.07K | 40.38K | 53.03K | 186.95K | 602.07K | 302.5K | 304.99K | 605.64K |
| Other Current Liabilities | 0 | 0 | 272.75K | -408.49K | 294.38K | 129.48K | 13.83K | 176.22K | 164.77K | 76.14M |
| Current Ratio | 1.66x | 2.54x | 0.40x | 0.07x | 0.16x | 9.09x | 6.02x | 2.55x | 0.62x | 0.62x |
| Quick Ratio | 1.48x | 2.26x | 0.33x | 0.06x | 0.13x | 8.97x | 5.91x | 2.43x | 0.51x | 0.51x |
| Cash Conversion Cycle | 135.82 | 755.86 | 9.08 | -1.96K | -808.7 | -384.22 | -290.38 | -448.96 | -166.95 | -1.38K |
| Total Non-Current Liabilities | 309.65K | 0 | 0 | 270.26K | 1.08M | 265.08K | 86.08K | 2.19M | 1.58M | 1.08M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.08M |
| Capital Lease Obligations | 0 | 0 | 0 | 270.26K | 845.13K | 239.66K | 86.08K | 2.13M | 1.56M | 4.21M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 309.65K | 0 | 0 | 0 | 235.71K | 25.41K | 0 | 63.46K | 23.49K | 23.49K |
| Total Liabilities | 1.88M | 932.34K | 3.66M | 11.14M | 10.42M | 3.51M | 3.97M | 6.15M | 5.18M | 80.57M |
| Total Debt | 0 | 0 | 1.63M | 5.99M | 5.87M | 879.33K | 180.32K | 2.73M | 2.13M | 1.7M |
| Net Debt | -1.76M | -766.19K | 1.47M | 5.83M | 5.2M | -27.32M | -21.89M | -6M | 1.4M | 1.52M |
| Debt / Equity | - | - | 30.58x | 0.53x | 2.22x | 0.02x | 0.01x | 0.33x | - | -0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.18x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.16x |
| Interest Coverage | -999999.00x | - | - | - | - | - | -2.44x | - | - | - |
| Total Equity | 923.68K▲ 0% | 2.69M▲ 191.4% | 53.47K▼ 98.0% | 11.23M▲ 20904.1% | 2.64M▼ 76.5% | 40.27M▲ 1423.7% | 21.77M▼ 45.9% | 8.27M▼ 62.0% | -202.61K▼ 102.4% | -77.43M▲ 0% |
| Equity Growth % | -77.54% | 191.43% | -98.01% | 20904.11% | -76.47% | 1423.67% | -45.94% | -62% | -102.45% | -4382.84% |
| Book Value per Share | 65.44 | 84.61 | 0.83 | 78.26 | 4.42 | 14.68 | 5.91 | 2.06 | -0.04 | -106.94 |
| Total Shareholders' Equity | 923.68K | 2.69M | 53.47K | 11.23M | 2.64M | 40.27M | 21.77M | 8.27M | -202.61K | -77.43M |
| Common Stock | 45.64K | 69.43K | 140.92K | 40.57K | 198.05K | 656.15K | 39.38K | 40.63K | 66.67K | 7.67K |
| Retained Earnings | -47.02M | -54.77M | -63.11M | -82.5M | -108.38M | -128.04M | -153.78M | -167.76M | -180.43M | -262.59M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 1.5K | -273.77K | -358.76K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
POAI Cash Flow Statement
Predictive Oncology Inc. (POAI) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.38M | -4.46M | -5.29M | -8.73M | -12.26M | -12.21M | -12.37M | -13.19M | -11.96M | -11.96M |
| Operating CF Margin % | -959.8% | -681.05% | -374.59% | -618.64% | -978.84% | -859.37% | -821.73% | -810.31% | -736.27% | - |
| Operating CF Growth % | 41.48% | -1.79% | -18.57% | -65.14% | -40.37% | 0.4% | -1.33% | -6.62% | 9.35% | 103.33% |
| Net Income | -6.53M | -7.75M | -10.09M | -19.39M | -25.88M | -19.66M | -25.74M | -12.02M | -10.86M | -84.33M |
| Depreciation & Amortization | 82.36K | 71.56K | 147.63K | 704.88K | 1.02M | 1.34M | 1.31M | 724.81K | 695.66K | 550.97K |
| Stock-Based Compensation | 886.6K | 4.04M | 1.46M | 0 | 1.17M | 921.13K | 522.44K | 0 | 0 | 0 |
| Deferred Taxes | 0 | -1.84K | 0 | 0 | -1.17M | -661.66K | -522.44K | 0 | 0 | 0 |
| Other Non-Cash Items | 1.62M | 359.13K | 3.77M | 8.08M | 13.81M | 7.04M | 11.19M | -1.12M | -876.57K | 75.75M |
| Working Capital Changes | 446K | -1.18M | 884.3K | 1.87M | -1.21M | -1.19M | 866.69K | -780.36K | -914.56K | -1.07M |
| Change in Receivables | -636 | -98.58K | -95.1K | 143.32K | 69.91K | -20.77K | 23K | 19K | -467.93K | -273.59K |
| Change in Inventory | -40.47K | 7.16K | 23.98K | 91.11K | -94.72K | -98.15K | -42.81K | -65.45K | 95.08K | 126.42K |
| Change in Payables | -430.3K | -79.65K | 305.23K | 365.77K | -1.66M | -350.3K | -78.32K | 399.21K | -191.15K | 1.88M |
| Cash from Investing | -422.86K | -1.65M | -1.11M | -599.09K | -167.46K | -10.61M | -475.7K | -302.37K | 22.49K | 657K |
| Capital Expenditures | -44.75K | -55.27K | -232K | -5.89K | -360.78K | -962.32K | -475.7K | -47.55K | -9.51K | 0 |
| CapEx % of Revenue | 9.8% | 8.44% | 16.43% | 0.42% | 28.81% | 67.74% | 31.6% | 2.92% | 0.59% | - |
| Acquisitions | -11.99K | 0 | 0 | 248.1K | 193.32K | -9.59M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -88.01K | -1.88M | -1.12M | -841.3K | 0 | -55K | 0 | -254.82K | 32K | 657K |
| Cash from Financing | 1.71M | 5.11M | 5.79M | 9.32M | 12.95M | 50.34M | 6.72M | 148.9K | 3.94M | 4.36M |
| Debt Issued (Net) | 0 | 0 | 2.19M | 1.54M | 1.29M | -5.24M | 0 | 150.41K | -150.41K | -8.4K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -1.51K | 1000K | 2.46M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -11.53K | -27.65K | -1.51K | 0 | 0 |
| Other Financing | 0 | 0 | 650.06K | -196.32K | 1.71M | 4.39M | 0 | 0 | 0 | 0 |
| Net Change in Cash | -3.09M▲ 0% | -997.9K▲ 67.7% | -604.04K▲ 39.5% | -11.32K▲ 98.1% | 527.5K▲ 4759.5% | 27.52M▲ 5117.9% | -6.13M▼ 122.3% | -13.34M▼ 117.6% | -7.99M▲ 40.1% | -2.9M▲ 0% |
| Free Cash Flow | -4.43M▲ 0% | -4.52M▼ 2.0% | -5.52M▼ 22.3% | -8.76M▼ 58.7% | -12.62M▼ 44.1% | -13.17M▼ 4.4% | -12.85M▲ 2.5% | -13.21M▼ 2.8% | -11.97M▲ 9.4% | -8.78M▲ 0% |
| FCF Margin % | -969.6% | -689.49% | -391.03% | -620.52% | -1007.65% | -927.11% | -853.33% | -811.63% | -736.86% | -1205.17% |
| FCF Growth % | 41.36% | -2.01% | -22.26% | -58.68% | -44.06% | -4.38% | 2.47% | -2.84% | 9.43% | 26.86% |
| FCF per Share | -313.58 | -141.91 | -86.14 | -61.04 | -21.12 | -4.80 | -3.49 | -3.29 | -2.19 | -2.19 |
| FCF Conversion (FCF/Net Income) | 0.67x | 0.58x | 0.52x | 0.45x | 0.47x | 0.62x | 0.48x | 0.94x | 0.98x | 0.10x |
| Interest Paid | 0 | 0 | 0 | 146.06K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
POAI Key Ratios
Predictive Oncology Inc. (POAI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -259.15% | -428.51% | -734.79% | -343.66% | -373.14% | -91.62% | -82.98% | -93.11% | -302.42% | 424.7% |
| Return on Invested Capital (ROIC) | - | -1070.64% | -341.61% | -182.7% | -152.74% | -147.45% | -304.68% | -847.75% | -473.83% | -473.83% |
| Gross Margin | 60.21% | 77.39% | 70.55% | 62.32% | 64.29% | 65.72% | 66.45% | 62.57% | 49.12% | 50.24% |
| Net Margin | -1429.59% | -1182.98% | -714.51% | -1373.71% | -2066.99% | -1383.65% | -1709.62% | -859.13% | -751.39% | -11581.34% |
| Debt / Equity | - | - | 30.58x | 0.53x | 2.22x | 0.02x | 0.01x | 0.33x | - | -0.02x |
| Interest Coverage | -999999.00x | - | - | - | - | - | -2.44x | - | - | - |
| FCF Conversion | 0.67x | 0.58x | 0.52x | 0.45x | 0.47x | 0.62x | 0.48x | 0.94x | 0.98x | 0.10x |
| Revenue Growth | -30.24% | 43.45% | 115.57% | -0.01% | -11.28% | 13.45% | 5.97% | 8.12% | -0.24% | -47.2% |
POAI Frequently Asked Questions
Predictive Oncology Inc. (POAI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Predictive Oncology Inc. (POAI) reported $0.7M in revenue for fiscal year 2024.
Predictive Oncology Inc. (POAI) saw revenue decline by 0.2% over the past year.
Predictive Oncology Inc. (POAI) reported a net loss of $84.3M for fiscal year 2024.
Dividend & Returns
Predictive Oncology Inc. (POAI) has a return on equity (ROE) of -302.4%. Negative ROE indicates the company is unprofitable.
Predictive Oncology Inc. (POAI) had negative free cash flow of $8.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More POAI
Predictive Oncology Inc. (POAI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates